Abstract:Background: In analytical performance studies, the choice of comparator method plays an important role, as studies have shown that there exist relevant systematic differences (bias) between laboratory analyzers. The feasibility of retrospective recalibration of measurement results through comparison with methods or materials of higher metrological order to minimize bias was therefore assessed. Method: Existing data from performance studies of continuous and blood glucose monitoring systems were retrospectively… Show more
“…Whereas a factory calibrated CGM device using venous glucose results for their algorithm should use a venous serum glucose measure, such as Yellow Spring Instrument (YSI) as the reference. Of note, Pleus et al 30 showed experimentally that BGM devices have analytical bias exceeding the acceptable levels defined in the Diabetes Laboratory Analysis Guidelines 46 . Pleus et al 30 also reported the analytical bias of the YSI analyser is above the optimal level 30 .…”
“…Of note, Pleus et al 30 showed experimentally that BGM devices have analytical bias exceeding the acceptable levels defined in the Diabetes Laboratory Analysis Guidelines 46 . Pleus et al 30 also reported the analytical bias of the YSI analyser is above the optimal level 30 . However, by using higher‐order mass spectrometry glucose readings to recalibrate retrospectively, the analytical bias of the YSI analysers and BGM devices reduced to optimal levels 30 .…”
“…Pleus et al 30 also reported the analytical bias of the YSI analyser is above the optimal level 30 . However, by using higher‐order mass spectrometry glucose readings to recalibrate retrospectively, the analytical bias of the YSI analysers and BGM devices reduced to optimal levels 30 . This new understanding presents a challenge when interpreting existing CGM accuracy studies while offering recalibration as a solution for the future.…”
“…Therefore, the IFCC Working group on CGM may provide the solution 38 . Once the IFCC team have established traceability, they aim to provide analytical performance criteria and standards along with statistical 10 and recalibration 30 methodologies to ensure consistency and validity. In lieu of the future publication of the ISO standards for CGM systems, we offer an overview of considerations for study design, point accuracy reporting, and point accuracy performance informed by the POCT05, 5 the iCGM criteria 43 and the discussion within this narrative review (Figure 2).…”
Section: Appraisal Of Conformité Européenne Markingmentioning
confidence: 99%
“…However, the performance standards will need to be lowered for non-adjunctive F I G U R E 2 Overview regarding an approach to evaluate design, reporting and performance of a CGM accuracy study critically. §Reference glucose readings from an accurate glucose analyser such as Yellow Spring Instrument or blood glucose monitor with readings recalibrated using a glucose measurement from a higher order method (mass spectrometry) 30 . †Paediatric performance data are required to be comparable.…”
Section: Applying Food and Drug Administration Integrated Continuous ...mentioning
The National Institute for Clinical Excellence updated guidance for continuous glucose monitoring (CGM) in 2022, recommending that CGM be available to all people living with type 1 diabetes. Manufacturers can trade in the UK with Conformité Européenne (CE) marking without an initial national assessment. The regulatory process for CGM CE marking, in contrast to the Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) process, is described. Manufacturers operating in the UK provided clinical accuracy studies submitted for CE marking. Critical appraisal of the studies shows several CGM devices have CE
“…Whereas a factory calibrated CGM device using venous glucose results for their algorithm should use a venous serum glucose measure, such as Yellow Spring Instrument (YSI) as the reference. Of note, Pleus et al 30 showed experimentally that BGM devices have analytical bias exceeding the acceptable levels defined in the Diabetes Laboratory Analysis Guidelines 46 . Pleus et al 30 also reported the analytical bias of the YSI analyser is above the optimal level 30 .…”
“…Of note, Pleus et al 30 showed experimentally that BGM devices have analytical bias exceeding the acceptable levels defined in the Diabetes Laboratory Analysis Guidelines 46 . Pleus et al 30 also reported the analytical bias of the YSI analyser is above the optimal level 30 . However, by using higher‐order mass spectrometry glucose readings to recalibrate retrospectively, the analytical bias of the YSI analysers and BGM devices reduced to optimal levels 30 .…”
“…Pleus et al 30 also reported the analytical bias of the YSI analyser is above the optimal level 30 . However, by using higher‐order mass spectrometry glucose readings to recalibrate retrospectively, the analytical bias of the YSI analysers and BGM devices reduced to optimal levels 30 . This new understanding presents a challenge when interpreting existing CGM accuracy studies while offering recalibration as a solution for the future.…”
“…Therefore, the IFCC Working group on CGM may provide the solution 38 . Once the IFCC team have established traceability, they aim to provide analytical performance criteria and standards along with statistical 10 and recalibration 30 methodologies to ensure consistency and validity. In lieu of the future publication of the ISO standards for CGM systems, we offer an overview of considerations for study design, point accuracy reporting, and point accuracy performance informed by the POCT05, 5 the iCGM criteria 43 and the discussion within this narrative review (Figure 2).…”
Section: Appraisal Of Conformité Européenne Markingmentioning
confidence: 99%
“…However, the performance standards will need to be lowered for non-adjunctive F I G U R E 2 Overview regarding an approach to evaluate design, reporting and performance of a CGM accuracy study critically. §Reference glucose readings from an accurate glucose analyser such as Yellow Spring Instrument or blood glucose monitor with readings recalibrated using a glucose measurement from a higher order method (mass spectrometry) 30 . †Paediatric performance data are required to be comparable.…”
Section: Applying Food and Drug Administration Integrated Continuous ...mentioning
The National Institute for Clinical Excellence updated guidance for continuous glucose monitoring (CGM) in 2022, recommending that CGM be available to all people living with type 1 diabetes. Manufacturers can trade in the UK with Conformité Européenne (CE) marking without an initial national assessment. The regulatory process for CGM CE marking, in contrast to the Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) process, is described. Manufacturers operating in the UK provided clinical accuracy studies submitted for CE marking. Critical appraisal of the studies shows several CGM devices have CE
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.